Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% sodium chloride solution Clear all
Recruiting Phase 2 Interventional

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

NCT07453069
View directory record Official record
Conditions
Vaginal Dysbiosis
Interventions
FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline)
Drug · Other
Lead sponsor
Freya Biosciences ApS
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Persistent Readiness Through Early Prediction Immunization Study

NCT05346302
View directory record Official record
Conditions
Inflammatory Response
Interventions
Pneumovax 23, Typhim VI, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Results available

Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery

NCT04333095
View directory record Official record
Conditions
Cardiovascular Surgery, Pain, Postoperative, Block
Interventions
Liposomal bupivacaine, Normal Saline Flush, 0.9% Injectable Solution_#1
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 17, 2026, 11:41 AM EDT
Recruiting Early Phase 1 Interventional

TEAPOT Study Multisite

NCT07565753
View directory record Official record
Conditions
Hemorrhage, Surgical, Tonsillar Bleeding
Interventions
Tranexamic Acid Injectable Product, Normal Saline
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
2 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Davis, California • Providence, Rhode Island • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 17, 2026, 11:41 AM EDT
Not yet recruiting Phase 1 Interventional

Magnesium Sulfate in Pediatric Burn Dressing Changes

NCT07126795
View directory record Official record
Conditions
Pediatric Burns
Interventions
magnesium sulfate, Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition

NCT02227329
View directory record Official record
Conditions
Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter, Bloodstream Infection Due to Hickman Catheter
Interventions
Ethanol, Heparin Lock, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans

NCT02537314
View directory record Official record
Conditions
Obesity
Interventions
benzocaine, placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Recruiting Phase 3 Interventional

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
56
States / cities
Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intranasal Insulin for Treatment of Alcohol Use Disorder

NCT05988632
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

NCT02650895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Efprezimod alfa, Saline
Biological · Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Prevention of Post Operative Bone Loss in Children

NCT00655681
View directory record Official record
Conditions
Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions
pamidronate, saline
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
4 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 17, 2026, 11:41 AM EDT
Withdrawn Phase 4 Interventional

Pharmacokinetic Profile and Dermatomal Coverage of the Erector Spinae Plane Block

NCT03874806
View directory record Official record
Conditions
Pain, Postoperative, Pain, Chest
Interventions
Ropivacaine 0.25%-NaCl 0.9% Injectable Solution, Ropivacaine 0.2%-NaCl 0.9% Injectable Solution
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 17, 2026, 11:41 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis

NCT02029040
View directory record Official record
Conditions
Acute Bronchiolitis
Interventions
3% Hypertonic Saline, 0.9 % normal saline
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Months to 12 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 17, 2026, 11:41 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery

NCT02266797
View directory record Official record
Conditions
Dysphagia After Anterior Cervical Decompression and Fusion of the Spine
Interventions
Dexamethasone, Saline
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
New York, New York • Westbury, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

NCT00846287
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized Helium-3, Placebo, Aformoterol
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 17, 2026, 11:41 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

NCT03608033
View directory record Official record
Conditions
IgA Nephropathy
Interventions
OMS721, Vehicle (D5W or saline)
Biological · Other
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
34
States / cities
Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 17, 2026, 11:41 AM EDT
Recruiting Phase 2 Interventional

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

NCT05952934
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)
Biological · Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
6
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT05645107
View directory record Official record
Conditions
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions
Xembify, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Not applicable Interventional

A Randomized, Equivalence Trial of Percutaneous Lumbar Adhesiolysis and Caudal Epidural Steroid Injections

NCT01053273
View directory record Official record
Conditions
Low Back Pain
Interventions
Caudal Epidural Injection, percutaneous adhesiolysis
Procedure
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization)

NCT01202656
View directory record Official record
Conditions
Infertility, Female
Interventions
G-CSF, Saline
Drug
Lead sponsor
Center for Human Reproduction
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 17, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

NCT03102021
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
erythropoietin, saline
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 17, 2026, 11:41 AM EDT